Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;23(4):617-626.
doi: 10.1007/s10689-024-00421-z. Epub 2024 Sep 11.

Endoscopic screening for identification of signet ring cell gastric cancer foci in carriers of germline pathogenic variants in CDH1

Lady Katherine Mejia Perez  1 , Margaret O'Malley  2   3 , Arjun Chatterjee  4 , Ruishen Lyu  5 , Qijun Yang  5 , Michael W Cruise  3   6 , Lisa LaGuardia  2   3 , David Liska  2   3 , Carole Macaron  1   3 , R Matthew Walsh  3   7 , Carol A Burke  8   9   10
Affiliations

Endoscopic screening for identification of signet ring cell gastric cancer foci in carriers of germline pathogenic variants in CDH1

Lady Katherine Mejia Perez et al. Fam Cancer. 2024 Nov.

Abstract

To determine the preoperative detection of signet ring cancer cells (SRC) on upper endoscopy (EGD) in patients with CDH1 pathogenic variant (PV) undergoing gastrectomy. To evaluate the development of advanced diffuse gastric cancer (DGC) in patients choosing surveillance. Guidelines recommend prophylactic total gastrectomy (pTG) in CDH1 PV carriers with family history of DGC between 18 and 40 years. Annual EGD with biopsies according to established protocols is recommended in carriers with no SRC and no family history of DGC, with consideration of pTG. Retrospective analysis of asymptomatic patients with CDH1 PVs with ≥ 1 surveillance EGD. Outcomes included pre-operative EGD detection of SRC, surgical stage, and progression to advanced DGC in those electing surveillance with EGD. 48 patients with CDH1 PVs who had ≥ 1 EGD were included. 24/ 48 (50%) underwent gastrectomy, including pTG in 7 patients. SRCC were detected on gastrectomy specimen in 21/24 (87.5%). SRCs were identified by EGD in 17/21 patients who had SRCC on gastrectomy specimens (sensitivity 81%, 17/21). All cancers were stage pT1a. The remaining 17 patients (50% with a family history of gastric cancer) continue in annual EGD surveillance with a median follow-up of 34.6 months. No SRCC or advanced DGC have been diagnosed. No CDH1 PV carriers without SRCC on random biopsies followed in an endoscopic program developed advanced DGC over a median follow up of 3 years. In the short term, EGD surveillance might be a safe alternative to immediate pTG in experienced hands in referral centers.

Keywords: CDH1; Endoscopy; Gastrectomy; Hereditary diffuse gastric cancer; Surveillance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of patients included in the study
Fig. 2
Fig. 2
a Schematic representation of the location of SRCC detected on EGD. b Schematic representation of the location of SRCC detected on surgical specimen
Fig. 3
Fig. 3
Kaplan Meier curve: Rate of patients with CDH1 PVs without SRCC detected in the Weiss Center since their first endoscopy. Patients who underwent prophylactic gastrectomy, did not have SCR found during the surveillance time, or were lost to follow-up were censored at the date of the last EGD
Fig. 4
Fig. 4
Diagram of the 17 individuals who continue endoscopic surveillance and their respective length of follow up
See this image and copyright information in PMC

References

    1. Roberts ME, Ranola JMO, Marshall ML et al (2019) Comparison of CDH1 Penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. JAMA Oncol 5(9):1325–1331. 10.1001/jamaoncol.2019.1208 - PMC - PubMed
    1. Xicola RM, Li S, Rodriguez N et al (2019) Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J Med Genet 56(12):838–843. 10.1136/jmedgenet-2019-105991 - PubMed
    1. Ryan CE, Fasaye GA, Gallanis AF et al (2024) Germline CDH1 Variants and Lifetime Cancer Risk. JAMA. Jun 14. 10.1001/jama.2024.10852. Epub ahead of print. PMID: 38873722 - PMC - PubMed
    1. Vos EL, Salo-Mullen EE, Tang LH et al (2020) Indications for total gastrectomy in CDH1 mutation carriers and outcomes of risk-reducing minimally invasive and open gastrectomies. JAMA Surg 155(11):1050–1057. 10.1001/jamasurg.2020.3356 - PMC - PubMed
    1. Friedman M, Adar T, Patel D et al (2021) Surveillance Endoscopy in the management of Hereditary diffuse gastric Cancer syndrome. Clin Gastroenterol Hepatol 19(1):189–191. 10.1016/j.cgh.2019.10.033 - PubMed